Table 2.

Response evaluation in all patients after ¹⁷⁷Lu-PRRT therapy.

Case no.	Symptoms	Anti-hypertensive (before)	Anti-hypertensive (after)	ΔDDD of antihypertensives (%)	ΔPFNMN (%)	ΔMean diametera (%)	Best response (RECIST 1.1)	SSTR-Response	∆STR-Rb SUVmax (%) on SSTR image
1	Stable	Amlodipine: 2.5 mg	Amlodipine: 12.5 mg	400	520	200	PD	PD	52.6
2	Stable	Prazosin: 7.5 mg, Amlodipine: 5 mg	Prazosin: 7.5 mg	−40	16.6	−7.2	SD	SD	−71.8
3	Improved	Prazosin: 5 mg, Metoprolol: 50 mg	Prazosin: 2.5 mg, Metoprolol: 25 mg	−50	−69.4	−16.3	MR	PR	−62.1
4	Improved	Prazosin: 20 mg, Atenolol: 50 mg	0	−100	−14.8	−22	MR	PR	−76.7
5	Worsened	Amlodipine: 10 mg	Prazosin: 30 mg, Metoprolo: 200 mg	266	1333	34.5	PD	PD	17.1
6	Improved	Prazosin: 20 mg Atenolol: 25 mg	0	−100	−17.3	−9.17	SD	SD	−50
7	Improved	Prazosin: 10 mg	0	−100	−89.7	−6	SD	SD	−18.3
8	Worsened	Amlodipine: 10 mg	Amlodipine: 10 mg, Prazosin: 15 mg	150	168	49.9	PD	PD	22.9
9	Improved	Prazosin: 30 mg, Amlodipine: 10 mg	Prazosin: 15 mg	−62.5	−45.2	−2.8	SD	SD	−41.5
10	Improved	NHTN	–	0	NA	NA	SD	SD	NA
11	Stable	NHTN	–	0	NA	−2.47	SD	SD	209
12	Improved	NHTN	–	0	NA	−8	SD	SD	–
13	Improved	NHTN	–	0	NA	−20	MR	PR	−75.3
14	Improved	NHTN	–	0	NA	−40	PR	PR	−76.3
15	Stable	NHTN	–	0	NA	−17	MR	SD	−1.7

^aChange in the longest diameter for non-nodal lesions and short axis for lymph nodes; ^bFor a patient having one lesion, single lesion SUVmax, and more than one lesion mean SUV_max were calculated.

DDD, defined daily dose; MR, minor response; NA, not available; NHTN, Normotensive; PD, progressive disease; PFNMN, plasma free normetanephrine; PR, partial response; SD, stable disease.